Inclusion Criteria:  Healthy male volunteers, aged between ≥ 19 and ≤ 45 years old at the time of screening.  Calculated body mass index (BMI) of ≥ 18.0 and ≤ 28.0 kg/m2  BMI = Weight(kg)/ Height(m)2 Individuals who agreed proper contraception during the study and did consent to not donation of sperm and ovum before the termination of study Individuals who voluntary decide to participate and agrees in writing to comply with the precautions after hearing and fully understanding the detailed explanation of this clinical trial  Exclusion Criteria:  History or presence of clinically significant and sever active cardiovascular, respiratory, hepatobiliary, renal, hematological, gastrointestinal, endocrine, immune, dermatologic, neurologic, or psychiatric disorder. Any medical history that may affect drug absorption, distribution, metabolism and excretion. Individuals who had history of hypersensitivity to Investigational drugs, derivative drugs or others drugs(aspirin and antibiotics etc.) Any clinically significant chronic medical illness. Any genetic disease including galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.  Individuals with one of the following laboratory test results in screening.  AST, ALT > UNL (upper normal limit) x 1.5 Creatinine clearance ≤ 60 mL/min Positive test results at HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL. Use of any prescription drugs and herbal preparations within 14 days prior to study drug administration and use of over-the-counter medications within 10 days prior to study drug administration. Individuals who cannot eat standard meal provided from clinical trial center. Donation of blood within 60 days prior to study drug administration or apheresis within 30 days prior to the first IP administration. Individuals who had received a blood transfusion within 60 days prior to study drug administration. Exposure to any investigational drug within 6 months prior to the first IP administration. Individuals taking any drugs inducing or inhibiting drug metabolizing enzymes including barbiturates within 30 days prior to the first IP administration. Individuals who had drinking (alcohol > 21unit/week) within 14 days prior to screening. Heavy smoking (more than 10 cigarettes/day) within 14 days prior to screening. Subjects having been deemed inappropriate for the trial as determined by the investigator.